Clinical Trials

Acute Myocardial Infarction

CardioCell’s initial focus is on chronic heart failure indications, but the company is currently exploring the application of our technologies to acute myocardial infarction (AMI). CardioCell itMSCs have successfully passed three phases of clinical trials on AMI patients in Kazakhstan via a study sponsored by CardioCell licensee ALTACO and registered for commercial use by Kazakh Ministry of Health.